Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration (Dry AMD)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Ocata Therapeutics Identifier:
First received: April 28, 2011
Last updated: October 21, 2015
Last verified: October 2015
This is a safety and tolerability trial to evaluate the effect of subretinal injection of human embryonic stem cell derived retinal pigment epithelium cells in patients with dry Age Related Macular Degeneration (AMD) and to perform exploratory evaluation of potential efficacy endpoints to be used in future studies retinal pigment epithelium (RPE) cellular therapy.

Condition Intervention Phase
Dry Age Related Macular Degeneration
Biological: MA09-hRPE
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Advanced Dry AMD

Resource links provided by NLM:

Further study details as provided by Ocata Therapeutics:

Primary Outcome Measures:
  • Safety of hESC derived RPE cells [ Time Frame: 12 Months ] [ Designated as safety issue: Yes ]

    The transplantation of hESC-derived RPE cells MA09-hRPE will be considered safe and tolerated in the absence of:

    • Any grade 2 (NCI grading system) or greater adverse event related to the cell product
    • Any evidence that the cells are contaminated with an infectious agent
    • Any evidence that the cells show tumorigenic potential

Secondary Outcome Measures:
  • exploratory evaluations for potential efficacy endpoints. [ Time Frame: 12 months ] [ Designated as safety issue: No ]

    Secondary endpoints will be evaluated as exploratory evaluations for potential efficacy endpoints.

    • Change in the mean of BCVA
    • Autofluorescence photography
    • Reading speed

    Evidence of successful engraftment will consist of:

    • Structural evidence (OCT imaging, fluorescein angiography, slit-lamp examination with fundus photography) that cells have been implanted in the correct location
    • Electroretinographic evidence (mfERG) showing enhanced activity in the implant location

Estimated Enrollment: 16
Study Start Date: April 2011
Estimated Study Completion Date: December 2015
Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MA09-hRPE

Experimental: Subretinal injection of MA09-hRPE

  • Cohort 1 50,000 cells
  • Cohort 2 100,000 cells
  • Cohort 2a Better Vision 100,000 cells
  • Cohort 3 150,000 cells
  • Cohort 4 200,000 cells
Biological: MA09-hRPE
Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells

Detailed Description:

This study is a Phase I/II, open-label, non randomized, sequential, multi-center clinical trial. There will be 5 cohorts, the 4 low vision cohorts will contain 3 patients, the better vision cohort will contain 4 patients. The enrolled cohorts will be as follows:

Three AMD patients- 50,000 MA09-hRPE cells transplanted Three AMD patients- 100,000 MA09-hRPE cells transplanted Four Better Vision AMD patients- 100,000 MA09-hRPE cells transplanted Three AMD patients- 150,000 MA09-hRPE cells transplanted Three AMD patients- 200,000 MA09-hRPE cells transplanted

Patients will be enrolled sequentially, and within each cohort of 3 patients, each patient's clinical course over the first 6 weeks following cell transplantation will be reviewed by an independent (DSMB) before enrollment is opened for the next 2 patients. A full safety assessment of all 3 patients in each cohort will be made by the DSMB when the 3rd patient in each cohort completes 4 weeks of follow-up, and before the first patient in the next cohort receives a cell transplant. The exception is the better vision group where all patients may be enrolled once DSMB approval has been received.

Each cohort will be enrolled sequentially in turn, with the exception of the better vision cohort which may be enrolled in parallel with the other cohorts.

The day of the cell implantation will be Day 0, and patients will remain in the study until the last visit at 12 months.


Ages Eligible for Study:   55 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult male or female over 55 years of age.
  • Patient should be in sufficiently good health to reasonably expect survival for at least four years after treatment
  • Clinical findings consistent with advanced dry AMD with evidence of one or more areas of >250microns of geographic atrophy (as defined in the Age-Related eye Disease Study [AREDS] study) involving the central fovea.
  • GA defined as attenuation or loss of RPE as observed by biomicroscopy, OCT, and FA.
  • No evidence of current or prior choroidal neovascularization in the treated eye
  • The visual acuity of the eye to receive the transplant will be no better than 20/400. The visual acuity of the eye in the better vision cohort to receive the transplant will be no better than 20/100.
  • The visual acuity of the eye that is not to receive the transplant will be no better than 20/400 for the worse vision patients and no worse than 20/100 for the better vision patients.
  • Electrophysiological findings consistent with advanced dry AMD.
  • Medically suitable to undergo vitrectomy and subretinal injection.
  • Medically suitable for general anesthesia or waking sedation, if needed.
  • Medically suitable for transplantation of an embryonic stem cell line:

Any laboratory value which falls slightly outside of the normal range will be reviewed by the Medical Monitor and Investigators to determine its clinical significance. If it is determined not to be clinically significant, the patient may be enrolled into the study.

  • Normal serum chemistry (sequential multi-channel analyzer 20 [SMA-20]) and hematology (complete blood count [CBC], prothrombin time [PT], and activated partial thromboplastin time [aPTT]) screening tests. (NOTE:With the exception of abnormalities specifically identified in the exclusion criteria)
  • Negative urine screen for drugs of abuse.
  • Negative human immunodeficiency virus (HIV), hepatitis B (HBV), hepatitis C (HCV) serologies.
  • No history of malignancy (with the exception of successfully treated (excised) basal cell carcinoma[skin cancer] or successfully treated squamous cell carcinoma of the skin).
  • Negative cancer screening within previous 6 months:
  • complete history & physical examination;
  • dermatological screening exam for malignant lesions;
  • negative fecal occult blood test & negative colonoscopy within previous 7 years;
  • negative chest roentgenogram (CXR);
  • normal CBC & manual differential;
  • negative urinalysis (U/A);
  • normal thyroid exam;
  • if male, normal testicular examination; digital rectal examination (DRE) and prostate specific antigen (PSA);
  • if female, normal pelvic examination with Papanicolaou smear; and
  • If female, normal clinical breast exam and, negative mammogram.
  • If female and of childbearing potential, willing to use two effective forms of birth control during the study.
  • If male, willing to use barrier and spermicidal contraception during the study.
  • Willing to defer all future blood, blood component or tissue donation.
  • Able to understand and willing to sign the informed consent

Exclusion Criteria:

  • Presence of active or inactive CNV in the eye to be treated.
  • Presence or history of retinal dystrophy, retinitis pigmentosa, chorioretinitis, central serious choroidopathy, diabetic retinopathy or other retinal vascular or degenerative disease other than ARMD.
  • History of optic neuropathy.
  • Macular atrophy due to causes other than AMD.
  • Presence of glaucomatous optic neuropathy in the study eye, uncontrolled IOP, or use of two or more agents to control IOP (acetazolamide, beta blocker, alpha-1-agonist, antiprostaglandins, anhydrous carbonic inhibitors).
  • Cataract of sufficient severity likely to necessitate surgical extraction within 1 year.
  • History of retinal detachment repair in the study eye.
  • Axial myopia of greater than -8 diopters
  • Axial length greater than 28 mm.
  • History of malignancy (with the exception of successfully treated [excised] basal cell carcinoma[skin cancer] or successfully treated squamous cell carcinoma of the skin).
  • History of myocardial infarction in previous 12 months.
  • History of diabetes mellitus.
  • History of cognitive impairments or dementia which may impact the patients ability participate in the informed consent process and to appropriately complete evaluations.
  • Any immunodeficiency.
  • Any current immunosuppressive therapy other than intermittent or low dose corticosteroids.
  • Alanine transaminase/aspartate aminotransferase (ALT/AST) >1.5 times the upper limit of normal or any known liver disease.
  • Renal insufficiency, as defined by creatine level >1.3 mg/dL.
  • A hemoglobin concentration of less than 10 gm/dL, a platelet count of less than 100k/mm3 or an absolute neutrophil count of less than 1000/mm3 at study entry.
  • Serologic evidence of infection with Hepatitis B, Hepatitis C, or HIV.
  • Current participation in any other clinical trial.
  • Participation within previous 6 months in any clinical trial of a drug by ocular or systemic administration.
  • Any other sight-threatening ocular disease.
  • Any history of retinal vascular disease (compromised blood-retinal barrier.
  • Glaucoma.
  • Uveitis or other intraocular inflammatory disease.
  • Significant lens opacities or other media opacity.
  • Ocular lens removal within previous 3 months.
  • Ocular surgery in the study eye in the previous 3 months
  • If female, pregnancy or lactation.
  • Any other medical condition, which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromises patient safety, or interferes with the interpretation of the study results.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01344993

United States, California
Jules Stein Eye Institute, UCLA School of Medicine
Los Angeles, California, United States, 90095
United States, Florida
Bascom Palmer Eye Institute
Miami, Florida, United States
United States, Massachusetts
Mass Eye and Ear
Boston, Massachusetts, United States
United States, Pennsylvania
Wills Eye Institute-Mid Atlantic Retina
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Ocata Therapeutics
Principal Investigator: Steven Schwartz, MD Jules Stein Eye Institute-UCLA
Principal Investigator: Carl D Regillo, MD Wills Eye Institute-Mid Atlantic Retina
Principal Investigator: Philip Rosenfeld, MD, PhD Bascom Palmer Eye Institute
Principal Investigator: Dean Eliott, MD Massachusetts Eye and Ear
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Ocata Therapeutics Identifier: NCT01344993     History of Changes
Other Study ID Numbers: ACT MA09-hRPE AMD-001 
Study First Received: April 28, 2011
Last Updated: October 21, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Ocata Therapeutics:
Geographic atrophy

Additional relevant MeSH terms:
Macular Degeneration
Eye Diseases
Retinal Degeneration
Retinal Diseases processed this record on May 26, 2016